TABLE 7.
Summary of AEs
| Preferred term, n (%) | Oral lead‐in cabotegravir 30 mg once daily (n = 19) | Cabotegravir long‐acting intramuscular injection 600 mg (n = 17) |
|---|---|---|
| Total AE a | 10 (53) | 17 (100) |
| Injection‐site pain | — | 15 (88) |
| Viral gastroenteritis | 3 (16) | 0 |
| Increased blood glucose | 2 (11) | 0 |
| Depression | 0 | 2 (12) |
| Headache | 0 | 2 (12) |
| Injection‐site erythema | — | 2 (12) |
| Insomnia | 0 | 2 (12) |
| Palpitations | 0 | 2 (12) |
| Pyrexia | 0 | 2 (12) |
| Fatigue | 1 (5) | 1 (6) |
| Drug‐related AE | 0 | 15 (88) |
| Injection‐site pain | — | 14 (82) |
| Injection‐site erythema | — | 2 (12) |
| Gait disturbance | 0 | 1 (6) |
| Injection‐site induration | — | 1 (6) |
| Injection‐site pruritus | — | 1 (6) |
| Injection‐site reaction | — | 1 (6) |
| Injection‐site swelling | — | 1 (6) |
| Insomnia | 0 | 1 (6) |
| Myalgia | 0 | 1 (6) |
AE, adverse event.
a
AEs reported in >1 participant.